Disclaimer
This article is an anonymised, composite educational discussion written in line with the Nursing and Midwifery Council’s expectations around confidentiality, professionalism and responsible social media use. It does not describe a single identifiable patient, admission, ward, date, clinician, hospital or organisation. Clinical details have been altered and generalised to preserve privacy and dignity. This article is not medical advice, not a prescribing protocol and not a substitute for senior Upper GI, HPB, radiology, endoscopy, pharmacy, dietetic or multidisciplinary decision-making. The pancreas and duodenum were both invited to cooperate. Neither returned the email.
Case background: John Doe and the persistently productive pancreas
John Doe was a man in his sixties admitted with severe acute necrotising pancreatitis complicated by sepsis, infected peri-pancreatic collections, nutritional failure and prolonged physiological instability. Cross-sectional imaging demonstrated complex collections with infected pseudocyst-like components, although in the context of necrotising pancreatitis these were more accurately understood as evolving walled-off necrotic collections rather than simple mature pseudocysts. This distinction matters because a pseudocyst is predominantly fluid, whereas walled-off necrosis may contain solid necrotic debris, infected tissue and enzyme-rich material (Banks et al., 2013).
Endoscopic cystgastrostomy was considered, but it was not appropriate at that stage. John was too unwell, the collection was insufficiently mature, and the anatomy was not favourable. The safest intervention was therefore radiologically guided percutaneous drainage as part of a minimally invasive step-up strategy. This is consistent with UK and European guidance, which supports endoscopic management when anatomically possible and percutaneous drainage when endoscopic drainage is not feasible or safe (NICE, 2018; Arvanitakis et al., 2018; Leppäniemi et al., 2019).
Over time, John required multiple percutaneous drains. These achieved partial source control but produced a familiar Upper GI problem: persistent enzyme-rich output in a patient already depleted by sepsis, inflammation and catabolism. The drains were working; unfortunately, so was the pancreas.
Nutrition: TPN as rescue, not nostalgia
Modern pancreatitis management no longer supports routine “pancreatic rest” for every patient. Enteral nutrition is preferred because it preserves gut barrier function and reduces infectious complications. NICE recommends enteral nutrition in severe or moderately severe acute pancreatitis and parenteral nutrition only when enteral feeding has failed or is contraindicated (NICE, 2018). This is broadly consistent with North American, Canadian and international guidance, which also prioritises enteral feeding while reserving parenteral nutrition for intolerance, contraindication or failure to meet nutritional requirements (Greenberg et al., 2016; Tenner et al., 2024; IAP/APA/EPC/IPC/JPS Working Group, 2025).
John could not tolerate oral intake. Enteral feeding was attempted or considered but was not clinically achievable because of symptoms, ileus risk, collection complexity and physiological instability. Total parenteral nutrition was therefore commenced not as a nostalgic return to “nil by mouth until the pancreas apologises”, but as rescue nutrition in a patient whose gastrointestinal route was temporarily unavailable.
Why octreotide in necrotising pancreatitis?
Octreotide is a synthetic somatostatin analogue. Its attraction in pancreatic practice lies in its inhibitory effect on gastrointestinal and pancreatic secretion. In practical Upper GI language, it is often used to “shut down” pancreatic and gastrointestinal secretory activity. The phrase is pharmacologically imprecise, but clinically recognisable: reduce secretory drive, reduce enzyme-rich output and make a chaotic situation more manageable.
The theoretical rationale is strong. Pancreatic duct disruption, infected necrotic collections and percutaneous drains can create a functional external pancreatic fistula. If exocrine secretion continues to feed that system, the patient may suffer fluid loss, electrolyte disturbance, skin damage, drain burden and worsening nutritional depletion. Octreotide is therefore not used to cure necrotising pancreatitis. It is used as an adjunct while drainage, antibiotics, nutritional support, imaging surveillance and time do the more fundamental work.
The evidence base is indirect. Octreotide is licensed in some pancreatic contexts, including prevention of complications following pancreatic surgery, where the Summary of Product Characteristics describes 100 micrograms three times daily by subcutaneous injection for seven consecutive days (Electronic Medicines Compendium, 2024a). Its use in necrotising pancreatitis with high-output percutaneous drainage is extrapolated from pancreatic fistula, enterocutaneous fistula and postoperative pancreatic surgery literature.
Gans et al. (2012) found no solid evidence that somatostatin analogues reliably increase pancreatic fistula closure rates compared with other treatments. Rahbour et al. (2012) reported improved time to closure in enterocutaneous fistulae, while Coughlin et al. (2012) found reduced fistula duration and hospital stay but no mortality benefit.
Gurusamy et al. (2012) similarly concluded that perioperative somatostatin analogues may reduce some complications without demonstrating a mortality benefit. The honest conclusion is therefore modest: octreotide may reduce output in selected secretory states, but it should not be presented as a definitive disease-modifying treatment.
The comparator case: ERCP-related retroperitoneal duodenal perforation
A useful comparison is a patient who develops a retroperitoneal duodenal perforation following ERCP. This is also an Upper GI/HPB-adjacent problem, often involving the same teams: gastroenterology, Upper GI surgery, HPB surgery, radiology, nutrition, pharmacy and intensive care. Unlike pancreatitis itself, ERCP-related perforation is uncommon, with systematic reviews reporting incidence below 1% in most series, but it is sufficiently recognised that most acute hospitals performing ERCP need a response pathway (Vezakis et al., 2015; Cirocchi et al., 2017).
Stapfer classification remains a practical way to frame ERCP perforations:
Type I injuries are lateral or medial duodenal wall perforations and are usually more severe.
Type II injuries are periampullary, often sphincterotomy-related and typically retroperitoneal.
Type III injuries involve the distal bile duct or guidewire injury, and type IV describes retroperitoneal air alone (Stapfer et al., 2000).
ESGE guidance emphasises rapid assessment, CT imaging, documentation of site and size, consideration of endoscopic closure where feasible, surgical consultation when closure fails or the patient deteriorates, and diversion or decompression when required (Paspatis et al., 2020).
The conservative management package for a sealed or contained retroperitoneal perforation commonly includes nil by mouth, intravenous fluids, broad-spectrum antibiotics, gastric decompression, percutaneous drainage of collections where present, nutritional support and close senior review. This overlaps strongly with the pancreatitis case: both scenarios involve leakage of biologically hostile fluid into places where nature did not intend it to go. The difference is the dominant fluid. In necrotising pancreatitis, the problem is pancreatic enzyme-rich inflammatory fluid. In ERCP perforation, the problem may be a mixed duodenal, biliary, pancreatic and enteric leak, with retroperitoneal contamination and sepsis risk.
Can Octreotide or Lanreotide be justified in ERCP perforation?
The mechanistic argument is similar but not identical. In John Doe’s pancreatitis, octreotide targets pancreatic exocrine output feeding percutaneous drains. In retroperitoneal duodenal perforation, the aim is broader: reduce pancreaticobiliary and upper gastrointestinal secretions passing across or near a perforation, reduce fistula output, and support containment while the retroperitoneum heals. The concept is attractive, especially where conservative management is being attempted and drain output is high.
However, the evidence is even thinner than in pancreatic fistula. Guidelines for ERCP-related perforation focus on recognition, classification, endoscopic closure, antibiotics, drainage, nutrition and surgery; they do not routinely recommend octreotide or lanreotide as standard therapy (Paspatis et al., 2020; Dumonceau et al., 2020).
Published support is mainly extrapolated from fistula literature and occasional duodenal perforation or upper GI leak reports rather than high-quality trials in ERCP perforation specifically. This makes the governance argument stronger, not weaker. If a medicine is being used because its physiology makes sense, but the direct evidence is limited, then the indication, dose, review point and stopping rule need to be written down.
The ethical comparison is also important. In both cases, clinicians may describe octreotide as a way to “dry up” secretions. Yet the patient experiences it as three painful injections per day, often on top of enoxaparin, insulin, antibiotics, blood tests, drains and central access. Injection-site pain is a recognised adverse effect (Electronic Medicines Compendium, 2024a; Alghamdi, Jawas and Hart, 2007). Lanreotide, administered at extended intervals in licensed indications, appears attractive because it reduces injection frequency (Electronic Medicines Compendium, 2024b). But it is more expensive, longer acting and usually off-label in this context. Pharmacy resistance is therefore not obstructive behaviour; it is stewardship in the absence of a policy.
Dose escalation and pharmacy governance
In practice, where no local guideline exists, octreotide dosing often comes from historical precedent. A cautious starting dose of 50 micrograms subcutaneously three times daily, escalating every few days by 50 micrograms TDS according to drain-output response, up to 200 micrograms TDS, is clinically pragmatic.
It mirrors the dose ranges used in secretory gastrointestinal disorders and fistula practice, although these are not specific to necrotising pancreatitis or ERCP perforation. A UK medicines-management review describes short-acting octreotide 50-150 micrograms two to three times daily for secretory gastrointestinal disorders and 100 micrograms three times daily for enterocutaneous fistulae; it also highlights cost differences between short-acting octreotide, octreotide LAR and lanreotide (Lancashire and South Cumbria Medicines Management Group, 2020).
The local policy should therefore include two linked decisions: first, when to start short-acting octreotide; second, when, if ever, to convert to lanreotide. Conversion should not be based simply on staff convenience or formulary anxiety. It should consider expected treatment duration, response to short-acting octreotide, injection burden, patient preference, cost, off-label governance and reversibility.
Short-acting octreotide is easier to stop if ineffective or harmful.
Lanreotide is more convenient but commits the patient and organisation to a longer pharmacological tail. That may be appropriate for prolonged secretory control, but it requires senior MDT and pharmacy agreement.
UK practice compared with other systems
The UK position is characterised by national principles but local operational gaps. NICE provides pancreatitis nutrition and intervention principles, and ESGE guidance heavily influences European endoscopic practice. However, octreotide for pancreatitis drains or ERCP perforation usually sits outside national guidance, leaving Trusts to create local policies. The familiar tertiary response, “use your local policy”, is reasonable only if the policy exists.
In the United States, ACG and AGA guidance similarly emphasise early enteral nutrition, avoidance of unnecessary intervention, and step-up drainage for infected or symptomatic necrosis; AGA specifically recognises percutaneous drainage for patients too ill for endoscopic or surgical intervention and for early infected collections (Baron et al., 2020; Tenner et al., 2024).
Canadian guidance also prioritises enteral over parenteral nutrition (Greenberg et al., 2016).
Japanese and international pancreatitis guidance similarly supports delayed intervention where possible, with endoscopic or percutaneous drainage once collections are encapsulated or when earlier intervention is necessary in selected deteriorating patients (IAP/APA/EPC/IPC/JPS Working Group, 2025).
Across systems, the convergence is striking: drain when needed, feed enterally when possible, use TPN when necessary, and avoid early invasive heroics. Across systems, the gap is also similar: somatostatin analogues are discussed far more clearly in NETs, variceal bleeding and pancreatic surgery than in complex pancreatitis drains or ERCP perforation leaks.
Discussion: same logic, different leak
The pancreatitis case and the ERCP perforation case share a clinical grammar. Both involve source control, nutritional compromise, sepsis risk, MDT dependence and biologically aggressive fluid escaping into vulnerable spaces. Both may require percutaneous drains. Both may force a temporary move to TPN when the gut cannot safely or adequately be used. Both create a plausible role for secretory suppression.
Yet the differences matter. Necrotising pancreatitis is primarily a pancreatic inflammatory and necrotic process in which the drain output is often pancreatic enzyme-rich. ERCP retroperitoneal perforation is primarily an iatrogenic hollow-viscus or periampullary injury in which the danger is ongoing duodenal, biliary and pancreatic contamination. Octreotide in the former is aimed mainly at pancreatic exocrine output; in the latter, it is an adjunct to reduce upper gastrointestinal and pancreaticobiliary flow across a contained leak. Neither indication should be treated as automatic.
A good local guideline would therefore include both indications under a broader heading: somatostatin analogue use in complex Upper GI/HPB leaks and high-output secretory drainage. It should define eligible scenarios, require senior Upper GI/HPB discussion, confirm that drainage and source-control strategy have been addressed, document why oral or enteral feeding is not possible, specify dose escalation, mandate daily output review, and include a clear stop point if there is no measurable benefit. It should also require pharmacy involvement when prolonged treatment or Lanreotide conversion is considered.
Final thoughts
John Doe’s necrotising pancreatitis and the comparator ERCP-related retroperitoneal perforation expose the same governance problem from two different anatomical angles. Octreotide is physiologically plausible, frequently useful and often clinically sensible. Lanreotide may reduce injection burden in prolonged cases. But neither should float in the grey zone between folklore and formulary anxiety.
The question is not whether Upper GI teams should ever use octreotide for complex pancreatic or duodenal leaks. The question is why hospitals performing ERCP, managing pancreatitis and accepting HPB-adjacent complications often lack a policy for a practice they already use.
For patients, such a policy could reduce pain and variation. For clinicians, it would reduce uncertainty. For pharmacy, it would provide governance. For the pancreas and duodenum, sadly, it would provide yet another document they will completely ignore.
References
Alghamdi, A.A., Jawas, A.M. and Hart, R.S. (2007) ‘Use of octreotide for the prevention of pancreatic fistula after elective pancreatic surgery: a systematic review and meta-analysis’, Canadian Journal of Surgery, 50(6), pp. 459-466.
Arvanitakis, M., Dumonceau, J.M., Albert, J. et al. (2018) ‘Endoscopic management of acute necrotizing pancreatitis: European Society of Gastrointestinal Endoscopy evidence-based multidisciplinary guideline’, Endoscopy, 50(5), pp. 524-546.
Banks, P.A., Bollen, T.L., Dervenis, C. et al. (2013) ‘Classification of acute pancreatitis – 2012: revision of the Atlanta classification and definitions by international consensus’, Gut, 62(1), pp. 102-111.
Baron, T.H., DiMaio, C.J., Wang, A.Y. and Morgan, K.A. (2020) ‘American Gastroenterological Association Clinical Practice Update: Management of Pancreatic Necrosis’, Gastroenterology, 158(1), pp. 67-75.e1.
Cirocchi, R., Kelly, M.D., Griffiths, E.A. et al. (2017) ‘A systematic review of the management and outcome of ERCP related duodenal perforations using a standardized classification system’, The Surgeon, 15(6), pp. 379-387.
Coughlin, S., Roth, L., Lurati, G. and Faulhaber, M. (2012) ‘Somatostatin analogues for the treatment of enterocutaneous fistulas: a systematic review and meta-analysis’, World Journal of Surgery, 36(5), pp. 1016-1029.
Dumonceau, J.M., Kapral, C., Aabakken, L. et al. (2020) ‘ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline’, Endoscopy, 52(2), pp. 127-149.
Electronic Medicines Compendium (2024a) Octreotide 500 micrograms/1 ml solution for injection: Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/375/smpc (Accessed: 30 June 2026).
Electronic Medicines Compendium (2024b) Lanreotide solution for injection in pre-filled syringe: Summary of Product Characteristics. Available at: https://www.medicines.org.uk/ (Accessed: 1 July 2026).
Gans, S.L., van Westreenen, H.L., Kiewiet, J.J.S., Rauws, E.A.J., Gouma, D.J. and Boermeester, M.A. (2012) ‘Systematic review and meta-analysis of somatostatin analogues for the treatment of pancreatic fistula’, British Journal of Surgery, 99(6), pp. 754-760.
Greenberg, J.A., Hsu, J., Bawazeer, M. et al. (2016) ‘Clinical practice guideline: management of acute pancreatitis’, Canadian Journal of Surgery, 59(2), pp. 128-140.
Gurusamy, K.S., Koti, R., Fusai, G. and Davidson, B.R. (2012) ‘Somatostatin analogues for pancreatic surgery’, Cochrane Database of Systematic Reviews, 6, CD008370.
IAP/APA/EPC/IPC/JPS Working Group and Bouwense, S. (2025) ‘International Association of Pancreatology Revised Guidelines on Acute Pancreatitis 2025: Supported and Endorsed by the American Pancreatic Association, European Pancreatic Club, Indian Pancreas Club, and Japan Pancreas Society’, Pancreatology, 25(6), pp. 770-814.
Lancashire and South Cumbria Medicines Management Group (2020) New Medicine Recommendation: Octreotide and Lanreotide for Unlicensed Use in Secretory Gastrointestinal Disorders. Preston: NHS Midlands and Lancashire Commissioning Support Unit.
Leppäniemi, A., Tolonen, M., Tarasconi, A. et al. (2019) ‘2019 WSES guidelines for the management of severe acute pancreatitis’, World Journal of Emergency Surgery, 14, article 27.
National Institute for Health and Care Excellence (2018) Pancreatitis: diagnosis and management. NICE guideline NG104. London: NICE.
Nursing and Midwifery Council (2025) Social media guidance. London: NMC.
Paspatis, G.A., Arvanitakis, M., Dumonceau, J.M. et al. (2020) ‘Diagnosis and management of iatrogenic endoscopic perforations: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement – Update 2020’, Endoscopy, 52(9), pp. 792-810.
Rahbour, G., Siddiqui, M.R.S., Ullah, M.R., Gabe, S.M., Warusavitarne, J. and Vaizey, C.J. (2012) ‘A meta-analysis of outcomes following use of somatostatin and its analogues for the management of enterocutaneous fistulas’, Annals of Surgery, 256(6), pp. 946-954.
Stapfer, M., Selby, R.R., Stain, S.C., Katkhouda, N., Parekh, D., Jabbour, N. and Garry, D. (2000) ‘Management of duodenal perforation after endoscopic retrograde cholangiopancreatography and sphincterotomy’, Annals of Surgery, 232(2), pp. 191-198.
Tenner, S., Vege, S.S., Sheth, S.G. and Sauer, B.G. (2024) ‘American College of Gastroenterology guidelines: management of acute pancreatitis’, American Journal of Gastroenterology, 119(3), pp. 419-437.
Vezakis, A., Fragulidis, G., Polydorou, A.A. et al. (2015) ‘Endoscopic retrograde cholangiopancreatography-related perforations: diagnosis and management’, World Journal of Gastrointestinal Endoscopy, 7(14), pp. 1135-1141.
Leave a Reply